Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Volume 50, Issue 4, Pages (April 2009)
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng,
An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: The future of chronic hepatitis.
Volume 67, Issue 2, Pages (August 2017)
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Immunotherapy of hepatocellular carcinoma
Hepatic CD141+IFNλ+ DC subset: One against all?
The yin and yang of evasion and immune activation in HCC
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Obesity, inflammation, and liver cancer
Geoffrey W McCaughan, Amany Zekry  Journal of Hepatology 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 137, Issue 4, Pages (October 2009)
Volume 52, Issue 3, Pages (March 2010)
Volume 57, Issue 1, Pages 6-8 (July 2012)
NS5A inhibitors in the treatment of hepatitis C
Agustín Albillos, Margaret Lario, Melchor Álvarez-Mon 
Hepatitis C-associated B-cell non-Hodgkin lymphomas
Natural history of hepatitis B
Regulatory T-cell directed therapies in liver diseases
Stephanos J. Hadziyannis  Journal of Hepatology 
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
David G. Bowen, Christopher M. Walker  Journal of Hepatology 
Mechanisms of HBV-related hepatocarcinogenesis
Kinetics of Intrahepatic Covalently Closed Circular DNA and Serum Hepatitis B Surface Antigen During Antiviral Therapy for Chronic Hepatitis B: Lessons.
Biology of the immunomodulatory molecule HLA-G in human liver diseases
Volume 68, Issue 3, Pages (March 2018)
How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?  Neil Rajoriya,
Marina Berenguer, Detlef Schuppan  Journal of Hepatology 
Volume 61, Issue 2, Pages (August 2014)
F. Li, P. Zhou, W. Deng, J. Wang, R. Mao, Y. Zhang, J. Li, J. Yu, F
From immunosuppression to tolerance
Regulatory T-cell directed therapies in liver diseases
Hepatitis C core protein – The “core” of immune deception?
Hepatocyte-like cells differentiated from human induced pluripotent stem cells (iHLCs) are permissive to hepatitis C virus (HCV) infection: HCV study.
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Targets for immunotherapy of liver cancer
Volume 53, Issue 4, Pages (October 2010)
Volume 68, Issue 3, Pages (March 2018)
The yin and yang of evasion and immune activation in HCC
Volume 45, Issue 4, Pages (October 2006)
Volume 39, Pages (January 2003)
Ming-Ling Chang, Yun-Fan Liaw  Journal of Hepatology 
Volume 120, Issue 4, Pages (March 2001)
Hepatitis B cure: From discovery to regulatory approval
Bin Gao, Hua Wang, Fouad Lafdil, Dechun Feng  Journal of Hepatology 
Percy A. Knolle, Robert Thimme  Gastroenterology 
Natural Killer Cell Memory
Volume 42, Issue 3, Pages (March 2005)
EASL Clinical Practice Guidelines on hepatitis E virus infection
Cannabinoid signaling and liver therapeutics
The role of quantitative hepatitis B surface antigen revisited
A View to Natural Killer Cells in Hepatitis C
Volume 50, Issue 4, Pages (April 2009)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Arjan Boltjes, Dowty Movita, André Boonstra, Andrea M. Woltman 
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Volume 67, Issue 5, Pages (November 2017)
Immunological techniques in viral hepatitis
Volume 64, Issue 6, Pages (June 2016)
Volume 55, Issue 5, Pages (November 2011)
Macrophage heterogeneity in liver injury and fibrosis
Chronic hepatitis B in children and adolescents
Silvia Affò, Ramón Bataller  Journal of Hepatology 
Cell-mediated immunity Regulation of the immune response
Chimeric mouse model of hepatitis B virus infection
HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection  Sara Ferrando-Martinez, Kelly Huang, Angie.
Presentation transcript:

Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: Perspectives and challenges  Marie-Louise Michel, Qiang Deng, Maryline Mancini-Bourgine  Journal of Hepatology  Volume 54, Issue 6, Pages 1286-1296 (June 2011) DOI: 10.1016/j.jhep.2010.12.031 Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Impairment of T-cell responses in chronic hepatitis B. T cells circulate in the liver through the sinusoidal network, in which they come into contact with hepatocytes and antigen-presenting cells (Kupffer cells and liver sinusoidal endothelial cells). During chronic hepatitis B virus infection, CD8 T cells in the liver encounter virus particles, viral antigens, and infected hepatocytes. They interact with infected hepatocytes and Kupffer cells through the T-cell receptor (TCR)-MHC class I-peptide complex. Hepatocytes over-expressing PD-L1 during chronic infection provide CD8 T cells with an inhibitory signal via the PD-1 pathway. This negative signal results in the impairment of T-cell functions: decreases in proliferation, cytotoxic function and in the production of anti-viral cytokines (IFN-γ and TNF-α). The presence of a large number of regulatory T cells (Tregs) and high levels of IL-10 secretion also contribute to T-cell exhaustion. Journal of Hepatology 2011 54, 1286-1296DOI: (10.1016/j.jhep.2010.12.031) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 2 General scheme of combined vaccination and antiviral drug treatment. In trials of combination treatment, patients suffering from chronic hepatitis B are enrolled and assigned to one of two groups (Groups A and B). Patients from both groups receive antiviral drugs. At the beginning of antiviral treatment or once HBV-DNA viral load has decreased to undetectable levels, multiple shots of the vaccine are administered to patients from group A. HBV DNA viral load, % HBeAg and HBsAg seroconversion are assessed. During antiviral treatment, viral and antigenic loads decrease and dysfunctional HBV-specific T cells are expected to recover. At the end of the clinical trial (after the last vaccine injection) treatment is stopped in both groups. ALT levels are continually monitored to ensure the rapid detection of liver damage. Viral rebound is expected in the patients of group B, whereas viremia control is expected in the patients of group A. In the patients of group A, HBV-specific and vaccine-activated T cells are expected to exert their antiviral functions, including the secretion of cytokines (IFN-γ, IL-2 and TNF-α) and proliferation. Journal of Hepatology 2011 54, 1286-1296DOI: (10.1016/j.jhep.2010.12.031) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Gene therapy for chronic HBV infection. An immunotherapy protocol is established, combining vaccination and liver gene therapy. A recombinant HBV virus (rHBV) is designed, both as a gene delivery vector and as an antigen carrier, for intrahepatic expression of a foreign antigenic polyepitope. In this strategy, functional poly-epitope-specific T-cell responses will be generated in patients by vaccination before applying rHBV gene therapy. An rHBV is created in which the viral core gene is disrupted by the insertion of the foreign antigenic sequence. This core-deficient virus is not competent for replication unless the host hepatocyte provides the wild-type viral capsid protein in trans. The rHBV specifically infects human hepatocytes, as does the wild-type virus (wtHBV). However, rHBV cannot replicate in healthy recipients, and is maintained in chronically infected patients only in hepatocytes persistently infected with wtHBV. In the presence of HBV liver-specific promoters, rHBV proteins (polymerase, L, M, S envelopes, HBx) and the foreign antigenic polyepitope are produced, processed and presented as peptides on liver cells. The presentation of the foreign epitopes recruits vigorous functional T-cell response to the liver that should compensate for the dysfunctional HBV-specific T-cell response observed during persistent viral infection. Journal of Hepatology 2011 54, 1286-1296DOI: (10.1016/j.jhep.2010.12.031) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2011 54, 1286-1296DOI: (10. 1016/j. jhep. 2010 Copyright © 2011 European Association for the Study of the Liver Terms and Conditions